These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38329411)

  • 21. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 spike engagement of ACE2 primes S2' site cleavage and fusion initiation.
    Yu S; Zheng X; Zhou B; Li J; Chen M; Deng R; Wong G; Lavillette D; Meng G
    Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34930824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
    Rowland R; Brandariz-Nuñez A
    Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
    Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
    Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
    Nat Chem Biol; 2021 Jan; 17(1):113-121. PubMed ID: 33082574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne.
    Murae M; Sakai S; Miyata N; Shimizu Y; Okemoto-Nakamura Y; Kishimoto T; Ogawa M; Tani H; Tanaka K; Noguchi K; Fukasawa M
    Biol Pharm Bull; 2024; 47(5):930-940. PubMed ID: 38692871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.
    Azad T; Singaravelu R; Taha Z; Jamieson TR; Boulton S; Crupi MJF; Martin NT; Fekete EEF; Poutou J; Ghahremani M; Pelin A; Nouri K; Rezaei R; Marshall CB; Enomoto M; Arulanandam R; Alluqmani N; Samson R; Gingras AC; Cameron DW; Greer PA; Ilkow CS; Diallo JS; Bell JC
    Mol Ther; 2021 Jun; 29(6):1984-2000. PubMed ID: 33578036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
    Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptide S4 is an entry inhibitor of SARS-CoV-2 infection.
    Liang Z; Wang J; Zhang H; Gao L; Xu J; Li P; Yang J; Fu X; Duan H; Liu J; Liu T; Ma W; Wu K
    Virology; 2024 Sep; 597():110149. PubMed ID: 38917689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
    Hoffmann M; Sidarovich A; Arora P; Krüger N; Nehlmeier I; Kempf A; Graichen L; Winkler MS; Niemeyer D; Goffinet C; Drosten C; Schulz S; Jäck HM; Pöhlmann S
    mBio; 2022 Jun; 13(3):e0036422. PubMed ID: 35467423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility.
    Das A; Dutta S; Sharma D; Pal A; Ganguli N; Majumdar SS
    Bioengineered; 2021 Dec; 12(1):4407-4419. PubMed ID: 34436976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
    Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spike Glycoprotein-Mediated Entry of SARS Coronaviruses.
    Wang L; Xiang Y
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33187074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
    Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L
    Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between ACE2 and SARS-CoV-2 S Protein: Peptide Inhibitors for Potential Drug Developments Against COVID-19.
    Dërmaku-Sopjani M; Sopjani M
    Curr Protein Pept Sci; 2021; 22(10):729-744. PubMed ID: 34530706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.